DNA repair and cytotoxic drugs: The potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients

Pharmacogenomics

Volumn 14, Issue 6, 2013, Pages 689-700

  Nogueira, Augusto ^a,b   Assis, Joana ^a,b   Catarino, Raquel ^a   Medeiros, Rui ^a,b,c,d  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b LPCC   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

cytotoxic drugs; DNA damage; DNA repair; genetic polymorphisms; NSCLC; overall survival; RAD51

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; GEFITINIB; GEMCITABINE; MITOMYCIN; PLATINUM COMPLEX; RAD51 PROTEIN; TAXANE DERIVATIVE;

5' UNTRANSLATED REGION; ALLELE; CANCER PROGNOSIS; CARCINOGENESIS; CHEMORADIOTHERAPY; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; DRUG RESPONSE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HOMOLOGOUS RECOMBINATION; HUMAN; LUNG NON SMALL CELL CANCER; PHARMACOGENOMICS; RECOMBINATION REPAIR; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DNA REPAIR; HUMANS; LUNG NEOPLASMS; POLYMORPHISM, GENETIC; RAD51 RECOMBINASE; TREATMENT OUTCOME;

EID: 84875993459     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.48     Document Type: Review

References (122)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893-2917 (2011).
2. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 123(1 Suppl.), 21S-49S (2003). (Pubitemid 36135701)
3. Rosell R, Felip E, Garcia-Campelo R, Balana C. The biology of non-small-cell lung cancer: identifying new targets for rational therapy. Lung Cancer 46(2), 135-148 (2004). (Pubitemid 39330407)
4. Gajra A, Newman N, Gamble GP, Abraham NZ, Kohman LJ, Graziano SL. Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease. Lung Cancer 42(1), 51-57 (2003). (Pubitemid 37153135)
5. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell 1(1), 49-52 (2002). (Pubitemid 41039175)
6. Mattson ME, Pollack ES, Cullen JW. What are the odds that smoking will kill you? Am. J. Public Health 77(4), 425-431 (1987). (Pubitemid 17044055)
7. Young RP, Hopkins R, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur. Respir. J. 30(4), 616-622 (2007). (Pubitemid 351194819)
8. Brody JS, Spira A. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc. Am. Thorac. Soc. 3(6), 535-537 (2006). (Pubitemid 44285546)
9. Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343(2), 78-85 (2000). (Pubitemid 30451850)
10. Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol. 22(2), 330-353 (2004). (Pubitemid 41095099)
11. Hsu DS, Balakumaran BS, Acharya CR et al. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J. Clin. Oncol. 25(28), 4350-4357 (2007). (Pubitemid 350013839)
12. Ko JC, Hong JH, Wang LH et al. Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells. Mol. Cancer Ther. 7(11), 3632-3641 (2008).
13. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122(3), 1037-1057 (2002).
14. Takenaka T, Yoshino I, Kouso H et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int. J. Cancer 121(4), 895-900 (2007). (Pubitemid 47106222)
15. Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 50(2), 211-219 (2005). (Pubitemid 41427896)
16. Kling J. PARP inhibitors blaze a trail in difficult-to-treat cancers. Nat. Biotechnol. 27(9), 784-786 (2009).
17. Saviozzi S, Ceppi P, Novello S et al. Non-small cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways. Cancer Res. 69(8), 3390-3396 (2009).
18. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 411(6835), 366-374 (2001). (Pubitemid 32467046)
19. Synowiec E, Stefanska J, Morawiec Z, Blasiak J, Wozniak K. Association between DNA damage, DNA repair genes variability and clinical characteristics in breast cancer patients. Mutat. Res. 648(1-2), 65-72 (2008).
20. Scagliotti G. Optimizing chemotherapy for patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 2(Suppl. 2), S86-S91 (2007).
21. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit. Rev. Oncol. Hematol. 63(1), 12-31 (2007). (Pubitemid 46810280)
22. Camps C, Sirera R, Iranzo V, Taron M, Rosell R. Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy. Clin. Lung Cancer 8(6), 369-375 (2007). (Pubitemid 46924057)
23. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 62(17), 4899-4902 (2002). (Pubitemid 34984411)
24. van de Vaart PJ, Belderbos J, de Jong D et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int. J. Cancer 89(2), 160-166 (2000). (Pubitemid 30185925)
25. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83(5), 584-594 (2008). (Pubitemid 351720831)
26. Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J. Natl Cancer Inst. 94(14), 1091-1099 (2002). (Pubitemid 34830729)
27. Lai SL, Hwang J, Perng RP, Whang-Peng J. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells. Oncol. Res. 7(1), 31-38 (1995).
28. Reardon JT, Vaisman A, Chaney SG, Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro- cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res. 59(16), 3968-3971 (1999). (Pubitemid 29393563)
29. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res. 58(6), 1120-1123 (1998). (Pubitemid 28183195)
30. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 275(31), 23899-23903 (2000). (Pubitemid 30624678)
31. Yin M, Yan J, Martinez-Balibrea E et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer. a systemic review and meta-analysis. Clin. Cancer Res. 17(6), 1632-1640 (2011).
32. Britten RA, Liu D, Tessier A, Hutchison MJ, Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int. J. Cancer 89(5), 453-457 (2000).
33. Shirota Y, Stoehlmacher J, Brabender J et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 19(23), 4298-4304 (2001). (Pubitemid 33096777)
34. Li Q, Yu JJ, Mu C et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res. 20(2A), 645-652 (2000). (Pubitemid 30240614)
35. Lord RV, Brabender J, Gandara D et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 8(7), 2286-2291 (2002). (Pubitemid 34753602)
36. Yu JJ, Lee KB, Mu C et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int. J. Oncol. 16(3), 555-560 (2000).
37. Lunn RM, Helzlsouer KJ, Parshad R et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21(4), 551-555 (2000). (Pubitemid 30214005)
38. Duell EJ, Wiencke JK, Cheng TJ et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21(5), 965-971 (2000). (Pubitemid 30265141)
39. Gurubhagavatula S, Liu G, Park S et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol. 22(13), 2594-2601 (2004). (Pubitemid 41103746)
40. Rosell R, Taron M, Camps C, Lopez-Vivanco G. Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today (Barc.) 39(10), 775-786 (2003). (Pubitemid 37500404)
41. Zhou W, Gurubhagavatula S, Liu G et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 10(15), 4939-4943 (2004). (Pubitemid 39099767)
42. Viguier J, Boige V, Miquel C et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin. Cancer Res. 11(17), 6212-6217 (2005). (Pubitemid 41262950)
43. Henning W, Sturzbecher HW. Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology 193(1-2), 91-109 (2003). (Pubitemid 37340146)
44. Vispe S, Cazaux C, Lesca C, Defais M. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res. 26(12), 2859-2864 (1998). (Pubitemid 28297517)
45. Connell PP, Jayathilaka K, Haraf DJ, Weichselbaum RR, Vokes EE, Lingen MW. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int. J. Oncol. 28(5), 1113-1119 (2006).
46. Schneider S, Park DJ, Yang D et al. Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. Pharmacogenet. Genomics 16(8), 555-563 (2006). (Pubitemid 44100200)
47. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat. Genet. 27(3), 247-254 (2001). (Pubitemid 32201842)
48. Haaf T, Golub EI, Reddy G, Radding CM, Ward DC. Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes. Proc. Natl Acad. Sci. USA 92(6), 2298-2302 (1995).
49. Liu Y, Maizels N. Coordinated response of mammalian Rad51 and Rad52 to DNA damage. EMBO Rep. 1(1), 85-90 (2000).
50. Tan TL, Essers J, Citterio E et al. Mouse Rad54 affects DNA conformation and DNA-damage-induced Rad51 foci formation. Curr. Biol. 9(6), 325-328 (1999). (Pubitemid 29181840)
51. Sung P, Klein H. Mechanism of homologous recombination: mediators and helicases take on regulatory functions. Nat. Rev. Mol. Cell Biol. 7(10), 739-750 (2006). (Pubitemid 44450458)
52. Jackson SP. Sensing and repairing DNA double-strand breaks. Carcinogenesis 23(5), 687-696 (2002). (Pubitemid 34567505)
53. Williams GJ, Lees-Miller SP, Tainer JA. Mre11-Rad50-Nbs1 conformations and the control of sensing, signaling, and effector responses at DNA double-strand breaks. DNA Repair (Amst.) 9(12), 1299-1306 (2010).
54. Daboussi F, Dumay A, Delacote F, Lopez BS. DNA double-strand break repair signalling: the case of RAD51 post-translational regulation. Cell Signal. 14(12), 969-975 (2002). (Pubitemid 35279421)
55. Kawabata M, Kawabata T, Nishibori M. Role of recA/RAD51 family proteins in mammals. Acta Med. Okayama 59(1), 1-9 (2005). (Pubitemid 40459842)
56. Thompson LH, Schild D. Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat. Res. 477(1-2), 131-153 (2001). (Pubitemid 32480197)
57. Takahashi E, Matsuda Y, Hori T et al. Chromosome mapping of the human (RECA) and mouse (Reca) homologs of the yeast RAD51 and Escherichia coli recA genes to human (15q15.1) and mouse (2F1) chromosomes by direct R-banding fluorescence in situ hybridization. Genomics 19(2), 376-378 (1994). (Pubitemid 24059334)
58. Wick W, Petersen I, Schmutzler RK et al. Evidence for a novel tumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer. Oncogene 12(5), 973-978 (1996). (Pubitemid 26104439)
59. Flygare J, Falt S, Ottervald J et al. Effects of HsRad51 overexpression on cell proliferation, cell cycle progression, and apoptosis. Exp. Cell Res. 268(1), 61-69 (2001). (Pubitemid 32678860)
60. Krejci L, Altmannova V, Spirek M, Zhao X. Homologous recombination and its regulation. Nucleic Acids Res. 40(13), 5795-5818 (2012).
61. Chen G, Yuan SS, Liu W et al. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J. Biol. Chem. 274(18), 12748-12752 (1999).
62. Holthausen JT, Wyman C, Kanaar R. Regulation of DNA strand exchange in homologous recombination. DNA Repair (Amst.) 9(12), 1264-1272 (2010).
63. San Filippo J, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. Annu. Rev. Biochem. 77, 229-257 (2008).
64. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 4(9), 665-676 (2004). (Pubitemid 39215065)
65. Richardson C, Stark JM, Ommundsen M, Jasin M. Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene 23(2), 546-553 (2004). (Pubitemid 38175009)
66. Raderschall E, Stout K, Freier S, Suckow V, Schweiger S, Haaf T. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res. 62(1), 219-225 (2002). (Pubitemid 34074008)
67. Maacke H, Jost K, Opitz S et al. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 19(23), 2791-2795 (2000). (Pubitemid 30339230)
68. Magnusson KP, Sandstrom M, Stahlberg M et al. p53 splice acceptor site mutation and increased HsRAD51 protein expression in Bloom's syndrome GM1492 fibroblasts. Gene 246(1-2), 247-254 (2000). (Pubitemid 30190178)
69. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 62(10), 2890-2896 (2002). (Pubitemid 34525776)
70. Arnaudeau C, Helleday T, Jenssen D. The RAD51 protein supports homologous recombination by an exchange mechanism in mammalian cells. J. Mol. Biol. 289(5), 1231-1238 (1999). (Pubitemid 29296702)
71. Xia SJ, Shammas MA, Shmookler Reis RJ. Elevated recombination in immortal human cells is mediated by HsRAD51 recombinase. Mol. Cell Biol. 17(12), 7151-7158 (1997). (Pubitemid 27505945)
72. Klein HL. The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst.) 7(5), 686-693 (2008).
73. Christodoulopoulos G, Malapetsa A, Schipper H, Golub E, Radding C, Panasci LC. Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia. Clin. Cancer Res. 5(8), 2178-2184 (1999). (Pubitemid 29399275)
74. Maacke H, Opitz S, Jost K et al. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int. J. Cancer 88(6), 907-913 (2000).
75. Collis SJ, Tighe A, Scott SD, Roberts SA, Hendry JH, Margison GP. Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res. 29(7), 1534-1538 (2001). (Pubitemid 32288501)
76. Ohnishi T, Taki T, Hiraga S, Arita N, Morita T. In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem. Biophys. Res. Commun. 245(2), 319-324 (1998). (Pubitemid 28418498)
77. Qiao GB, Wu YL, Yang XN et al. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br. J. Cancer 93(1), 137-143 (2005).
78. Slupianek A, Schmutte C, Tombline G et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol. Cell 8(4), 795-806 (2001). (Pubitemid 33030213)
79. Feng Z, Scott SP, Bussen W et al. Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proc. Natl Acad. Sci. USA 108(2), 686-691 (2011).
80. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035), 917-921 (2005). (Pubitemid 40559006)
81. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5(9), 689-698 (2005). (Pubitemid 41486362)
82. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035), 913-917 (2005). (Pubitemid 40559005)
83. Birkelbach M, Ferraiolo N, Gheorghiu L et al. Detection of impaired homologous recombination repair in NSCLC cells and tissues. J. Thorac. Oncol. 8(3), 279-286 (2013).
84. Michels J, Vitale I, Senovilla L et al. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle doi:10.4161/cc.24034 (2013) (Epub ahead of print).
85. Paul I, Savage KI, Blayney JK et al. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. J. Pathol. 224(4), 564-574 (2011).
86. Ko JC, Ciou SC, Cheng CM et al. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells. Carcinogenesis 29(7), 1448-1458 (2008).
87. Chakravarti A. To a future of genetic medicine. Nature 409(6822), 822-823 (2001).
88. Mohrenweiser HW, Xi T, Vazquez-Matias J, Jones IM. Identification of 127 amino acid substitution variants in screening 37 DNA repair genes in humans. Cancer Epidemiol. Biomarkers Prev. 11(10 Pt 1), 1054-1064 (2002). (Pubitemid 35192657)
89. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev. 11(12), 1513-1530 (2002). (Pubitemid 36020002)
90. Matullo G, Peluso M, Polidoro S et al. Combination of DNA repair gene single nucleotide polymorphisms and increased levels of DNA adducts in a population-based study. Cancer Epidemiol. Biomarkers Prev. 12(7), 674-677 (2003). (Pubitemid 36899852)
91. Hung RJ, Brennan P, Canzian F et al. Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study. J. Natl Cancer Inst. 97(8), 567-576 (2005). (Pubitemid 40723784)
92. Misra RR, Ratnasinghe D, Tangrea JA et al. Polymorphisms in the DNA repair genes XPD, XRCC1, XRCC3, and APE/ref-1, and the risk of lung cancer among male smokers in Finland. Cancer Lett. 191(2), 171-178 (2003). (Pubitemid 36255602)
93. Shen H, Spitz MR, Qiao Y et al. Smoking, DNA repair capacity and risk of nonsmall cell lung cancer. Int. J. Cancer 107(1), 84-88 (2003). (Pubitemid 37100089)
94. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7(8), 573-584 (2007). (Pubitemid 47106628)
95. Wei Q, Frazier ML, Levin B. DNA repair: a double-edged sword. J. Natl Cancer Inst. 92(6), 440-441 (2000). (Pubitemid 30182874)
96. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346(2), 92-98 (2002). (Pubitemid 34438899)
97. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J. Clin. Oncol. 23(1), 175-183 (2005). (Pubitemid 41702636)
98. Xu JL, Hu LM, Huang MD et al. Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese. Asian Pac. J. Cancer Prev. 13(3), 851-856 (2012).
99. Kim SH, Lee GW, Lee MJ et al. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy. Lung Cancer 77(3), 578-584 (2012).
100. Ryu JS, Hong YC, Han HS et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44(3), 311-316 (2004).
101. Sancar A. DNA repair in humans. Annu. Rev. Genet. 29, 69-105 (1995). (Pubitemid 26005337)
102. Hasselbach L, Haase S, Fischer D, Kolberg HC, Sturzbecher HW. Characterisation of the promoter region of the human DNA-repair gene Rad51. Eur. J. Gynaecol. Oncol. 26(6), 589-598 (2005). (Pubitemid 43028049)
103. Rollinson S, Smith AG, Allan JM et al. RAD51 homologous recombination repair gene haplotypes and risk of acute myeloid leukaemia. Leuk. Res. 31(2), 169-174 (2007). (Pubitemid 44854198)
104. Blasiak J, Przybylowska K, Czechowska A et al. Analysis of the G/C polymorphism in the 5́-untranslated region of the RAD51 gene in breast cancer. Acta Biochim. Pol. 50(1), 249-253 (2003). (Pubitemid 37034247)
105. Levy-Lahad E, Lahad A, Eisenberg S et al. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc. Natl Acad. Sci. USA 98(6), 3232-3236 (2001). (Pubitemid 32220828)
106. Poplawski T, Arabski M, Kozirowska D et al. DNA damage and repair in gastric cancer-a correlation with the hOGG1 and RAD51 genes polymorphisms. Mutat. Res. 601(1-2), 83-91 (2006). (Pubitemid 44528596)
107. Kadouri L, Kote-Jarai Z, Hubert A et al. A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br. J. Cancer 90(10), 2002-2005 (2004). (Pubitemid 38746344)
108. Chakravarti D, Lamorte VJ, Nelson MC et al. Role of CBP/P300 in nuclear receptor signalling. Nature 383(6595), 99-103 (1996). (Pubitemid 26296470)
109. Webb PM, Hopper JL, Newman B et al. Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 14(2), 319-323 (2005). (Pubitemid 40270091)
110. Seedhouse C, Faulkner R, Ashraf N, Das-Gupta E, Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin. Cancer Res. 10(8), 2675-2680 (2004). (Pubitemid 38509141)
111. Nogueira A, Catarino R, Coelho A, Araujo A, Gomes M, Medeiros R. Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy. Cancer Chemother. Pharmacol. 66(3), 501-506 (2010).
112. Yin M, Liao Z, Huang YJ et al. Polymorphisms of homologous recombination genes and clinical outcomes of non-small cell lung cancer patients treated with definitive radiotherapy. PLoS ONE 6(5), e20055 (2011).
113. Popanda O, Schattenberg T, Phong CT et al. Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Carcinogenesis 25(12), 2433-2441 (2004). (Pubitemid 39625184)
114. Slupianek A, Hoser G, Majsterek I et al. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol. Cell Biol. 22(12), 4189-4201 (2002). (Pubitemid 34556589)
115. Bello VE, Aloyz RS, Christodoulopoulos G, Panasci LC. Homologous recombinational repair vis-a-vis chlorambucil resistance in chronic lymphocytic leukemia. Biochem. Pharmacol. 63(9), 1585-1588 (2002). (Pubitemid 34457997)
116. Wei Q, Cheng L, Hong WK, Spitz MR. Reduced DNA repair capacity in lung cancer patients. Cancer Res. 56(18), 4103-4107 (1996). (Pubitemid 26304997)
117. Grossman L, Wei Q. DNA repair and epidemiology of basal cell carcinoma. Clin. Chem. 41(12 Pt 2), 1854-1863 (1995).
118. Spitz MR, McPherson RS, Jiang H et al. Correlates of mutagen sensitivity in patients with upper aerodigestive tract cancer. Cancer Epidemiol. Biomarkers Prev. 6(9), 687-692 (1997). (Pubitemid 27427623)
119. Sellers TA, Potter JD, Bailey-Wilson JE, Rich SS, Rothschild H, Elston RC. Lung cancer detection and prevention: evidence for an interaction between smoking and genetic predisposition. Cancer Res. 52(Suppl. 9), 2694S-2697S (1992).
120. Perera FP. Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. J. Natl Cancer Inst. 88(8), 496-509 (1996). (Pubitemid 26118720)
121. de las Peñas R, Sanchez-Ronco M, Alberola V et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann. Oncol. 17(4), 668-675 (2006).
122. O'Donovan PJ, Livingston DM. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 31(6), 961-967 (2010).